EP
DFTX

Eversept Partners’s Definium Therapeutics DFTX Stock Holding History

Eversept Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.04M Buy
+160,723
New +$2.73M 0.16% 74

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners's DFTX Position: Q1 2026 in Review

Eversept Partners opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 160,723 shares worth $3.04M. The stake represents 0.16% of the portfolio and ranks #74 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Eversept Partners held 160,723 shares of Definium Therapeutics worth $3.04M as of Q1 2026.
  • Definium Therapeutics was a new Eversept Partners position in Q1 2026.
  • Definium Therapeutics made up 0.16% of Eversept Partners's portfolio in Q1 2026, its #74 holding.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.